Mesoblast (Mesoblast) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Mesoblast FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mesoblast's Free Cash Flow for the three months ended in Dec. 2023 was $-0.02 Mil. Mesoblast's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Mesoblast's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Mesoblast's current FCF Yield % is -6.30%.

The historical rank and industry rank for Mesoblast's FCF Margin % or its related term are showing as below:

MEOBF' s FCF Margin % Range Over the Past 10 Years
Min: -4927 Med: -483.26 Max: -166.58
Current: -776.71

During the past 13 years, the highest FCF Margin % of Mesoblast was -166.58%. The lowest was -4927.00%. And the median was -483.26%.

MEOBF's FCF Margin % is ranked worse than
72.78% of 1036 companies
in the Biotechnology industry
Industry Median: -148.935 vs MEOBF: -776.71

Mesoblast FCF Margin % Historical Data

The historical data trend for Mesoblast's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast FCF Margin % Chart

Mesoblast Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-347.26

-166.58

-1,377.40

-646.50

-847.66

Mesoblast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-832.73	-840.12	-762.74	-	-

Competitive Comparison of Mesoblast's FCF Margin %

For the Biotechnology subindustry, Mesoblast's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mesoblast's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mesoblast's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mesoblast's FCF Margin % falls into.

Mesoblast FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mesoblast's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-63.583	/	7.501
	=	-847.66 %

Mesoblast's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.019	/	0
	=	%

Mesoblast FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mesoblast's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast (Mesoblast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MESO:USA LWB:Germany MSB:Australia

Address

Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.